New York Life Lifts Citizens Financial Stake 1,253% in Q3

New York Life Investment Management LLC raised its stake in Citizens Financial Group (NYSE:CFG) by 1,253.0% during the third quarter, buying an additional 792,550 shares to reach 855,803 shares, worth $54,566,000 at the most recent SEC filing. The position equals 0.20% of the bank's stock. The disclosure, filed with the Securities and Exchange Commission, shows one of the sharpest single-quarter position builds among CFG's institutional holders this year.

One caveat belongs here before the cheer: a 1,253% rise on a small base still yields a modest holding. At $54.6 million, New York Life's stake ranks far below the fund's peers in the same name.

Who else bought, and by how much?

Several institutions moved in the same direction, though at very different scales:

• Robeco Institutional Asset Management B.V. lifted its stake by 7,979.7% in the third quarter, adding 12,014,785 shares to hold 12,165,352 shares valued at $775,663,000.
• Assenagon Asset Management S.A. raised its position 1,252.4% in the third quarter, adding 8,523,938 shares to reach 9,204,563 shares worth $586,883,000.
• BlackRock Inc. opened a new position in the second quarter worth roughly $3,415,046,000.
• Amundi boosted holdings 31.2% in the second quarter, adding 875,666 shares to hold 3,685,819 shares valued at $258,265,000.
• Dimensional Fund Advisors LP added 28,602 shares in the first quarter, a 0.6% increase, to hold 4,719,160 shares worth $282,927,000.

Institutions and hedge funds together own 94.90% of the stock. That figure signals deep institutional sponsorship; it also means the register leaves little room for retail flows to move the price.

What do the earnings and the balance sheet show?

CFG opened at $64.91 on Wednesday, down 0.3%. The market capitalization stands at $27.21 billion, with a price-to-earnings ratio of 13.06, a price-to-earnings-growth ratio of 0.59 and a beta of 0.74. The debt-to-equity ratio sits at 0.74; the current and quick ratios both read 0.86. The stock has traded between a one-year low of $49.00 and a one-year high of $75.33, and closed Wednesday below both its fifty-day moving average of $65.70 and its 200-day average of $65.65.

On October 16, the bank reported quarterly EPS of $1.41, beating the consensus estimate of $1.39 by $0.02. Revenue came in at $2.32 billion, short of the $2.34 billion analysts expected. Return on equity reached 9.52% and net margin 18.07%. A year earlier the firm earned $1.05 per share. Sell-side analysts forecast 5.30 EPS for the full year.

The EPS beat rests on a $0.02 margin; the revenue line missed. Both facts deserve equal weight.

Is the dividend doing the work?

The bank raised its quarterly dividend to $0.52 from $0.46, payable November 13 to stockholders of record on October 30, with the same ex-dividend date. The payout annualizes to $2.08, a yield of 3.2%, on a payout ratio of 41.85%. An increase of six cents per quarter is real cash; it also commits roughly 42% of earnings to shareholders before any reinvestment.

What are analysts saying?

Five brokerages trimmed their targets even as most kept positive ratings:

• UBS Group cut its target from $82.00 to $77.00 on October 5, rating the stock "buy."
• Jefferies Financial Group dropped its target from $90.00 to $80.00 on September 24, rating it "buy."
• Raymond James Financial lowered its target from $77.00 to $76.00 on October 19, with an "outperform" rating.
• Royal Bank of Canada cut its target from $79.00 to $74.00 on October 19, rating it "outperform."
• Stephens decreased its target from $70.00 to $65.00 on October 20, setting an "equal weight" rating.

Seventeen analysts rate the stock Buy and four rate it Hold, producing a MarketBeat average rating of "Moderate Buy" and an average target price of $76.79.

Every target moved down; no analyst raised one. The institutional buying and the falling targets tell two different stories, and the price will decide which one holds.